Drug interaction study for people starting immunotherapy
Part of Cancer, Digestive system, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at how common medicines might interact with immunotherapy (a treatment that helps your immune system fight cancer). Participation could help doctors learn how to better manage side effects and dosing for patients on these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have cancer and are about to start treatment with an immunotherapy drug (like pembrolizumab, nivolumab, ipilimumab, or others).
- You are not pregnant or breastfeeding.
- Your weight is between 50 kg (about 110 lbs) and your body mass index (BMI) is 35 or less.
- Your blood counts, liver, and kidney function are within normal ranges.
- You do not have an autoimmune disease (like lupus, Crohn's disease, multiple sclerosis, or type 1 diabetes).
- You are willing to avoid tobacco, marijuana, and limit alcohol to no more than 2 drinks a day during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
This study looks at how well immunotherapy (a type of cancer treatment that helps your immune system attack cancer cells) works for people with various types of cancer. You may join if you are already planning to receive this treatment, and the study will track your outcomes to help improve future care.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Hear when a new Genitourinary Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.